1 2	Title: Evaluating the Portability of SepsisWatch: A Multi-Site External Validation of a Sepsis Machine Learning Model
3	
4	
5 6	Bruno Valan, MENG ¹ ; Anusha Prakash, MS ² ; William Ratliff, MBA ¹ ; Michael Gao, MS ¹ ; Srikanth Muthva ² : Aiit Thomas, MBA ² : Jennifer L. Eaton, PhD ³ : Matt Gardner ¹ : Marshall
7	Nichols, MS ¹ : Mike Revoir ¹ : Dustin Tart, RN ⁴ : Cara O'Brien, MD ^{4,5} : Manesh Patel, MD ⁵ :
8	Suresh Balu, MS, MBA ¹ : Mark Sendak, MPP, MD ¹
9	
10	Address Correspondence to:
11	Mark Sendak
12	¹ Duke Institute for Health Innovation
13	300 West Morgan St. Durham, North Carolina
14	Phone: (919) 684-4389
15	Email: <u>mark.sendak@duke.edu</u>
16	
17	Affiliations
18	2
19	² Cohere Med Inc.
20	571 Euclid Ave
21	Berkeley, CA 94708
22	30 U U D 1 0 U
23	Summa Health Research & Innovation,
24 25	Summa Health, Akron, OH 44310
25 26	⁴ Duka University Hegnital
20 27	Durke University Hospital
27 28	Dumain, NC 27701
20	⁵ Department of Medicine
30	Duke University School of Medicine
31	Durham, NC, United States
32	
33	
34	
35	
36	
37	
38	
39	
40	Study Type: Diagnostic/Prognostic Study
41	
42	
43	
44	
45	

46 Abstract

47

48 **Importance:** Sepsis accounts for a substantial portion of global deaths and healthcare costs.

- Early detection using machine learning (ML) models offers a critical opportunity to improve careand reduce the burden of sepsis.
- 51
- 52 **Objective:** To externally validate the SepsisWatch ML model, initially developed at Duke
- 53 University, in a community healthcare and assess its performance and clinical utility in early 54 sepsis detection.
- 55

Design: This retrospective external validation study evaluated the performance of the

57 SepsisWatch model in a new environment. Data from patient encounters at Summa Health's 58 emergency departments between 2020 and 2021 were used. The study analyzed the model's

- ability to predict sepsis using a combination of static and dynamic patient data.
- 60
- 61 Setting: The study was conducted at Summa Health, a nonprofit healthcare system in Northeast
- 62 Ohio, covering two emergency departments (EDs) associated with acute care hospitals, and two
- 63 standalone EDs.
- 64

65 Participants: Encounters associated with adult patients in any of Summa Health's four EDs
66 were included. Encounters lasting <1 hour were excluded. Only the first 36 hours of each
67 encounter were used in model evaluation.

- 68
- 69 Intervention(s)/Exposure(s): The SepsisWatch model was used to predict sepsis based on
 70 patient data.
- 71

Main Outcome(s) and Measure(s): The primary outcomes measured were the model's area
 under the precision-recall curve (AUPRC), and area under the receiver operator curve (AUROC).

- **Results:** The study included 205,005 encounters from 101,584 unique patients. 54.7% (n =
- 76 112,223) patients were female and the mean age was 50 (IQR, [38,71]). The model demonstrated
- 57 strong performance across the Summa Health system, with little variation across different sites.
- The AUROC ranged from 0.906 to 0.960, and the AUPRC ranged from 0.177 to 0.252 across thefour sites.
- 80
- 81 **Conclusions and Relevance:** The external validation of the SepsisWatch model in a community
- 82 health system setting confirmed its robust performance and portability across different
- 83 geographical and demographic contexts. The study underscores the potential of advanced ML
- 84 models in improving sepsis detection in both academic and community hospital settings, paving
- the way for prospective studies to measure the clinical and operational impact of such models inhealthcare.
- 87
- 88
- 89
- 90

- 91 Introduction
- 92

94 Sepsis is a systemic inflammatory response to disseminated infection that affects millions of people worldwide.¹ Despite medical advancements, sepsis continues to be a major health 95 concern, accounting for 19.7% of all global deaths.² In the US, sepsis is the cause of up to half of 96 all in-hospital fatalities.³ The economic impact of sepsis is equally staggering. Between 2012 and 97 98 2018, the annual cost of inpatient hospitalizations related to sepsis for Medicare beneficiaries increased 26.12% from \$17.8 billion to \$22.4 billion.⁴ Costs for each sepsis-related encounter 99 100 were estimated to be \$18,023 when identified before admission and \$51,022 if recognized postadmission.⁵ Importantly, early detection and prompt antibiotic treatment can significantly reduce 101 both the cost and the health impacts of sepsis.⁶⁻¹¹ Sepsis care bundles have been developed and 102 103 diffused to advance the standard of care for sepsis management, but the outcomes of these interventions are mixed.¹²⁻¹⁴ Leveraging machine learning (ML) for early sepsis identification 104 105 has become a pivotal opportunity to further improve sepsis care. 106 ML models can effectively identify sepsis early and implementation of these models can influence treatment and outcomes.¹⁵⁻¹⁸ Prospective implementation of ML and non-ML driven 107 108 sepsis alert systems have been shown to decrease in-hospital mortality, organ failure, and length of stay.^{19,22,24} However, other studies demonstrate that while these systems may be able to predict 109 impending sepsis they can fall short of changing care delivery and patient outcomes.²³ The role 110 111 of ML in sepsis treatment merits continued study of models and implementation approaches in different healthcare settings and patient populations. 112

A key challenge to scaling ML models in healthcare is lack of portability, in part due to significant variability of patient populations and care delivery processes across geographies and points in time. Performance of ML models across diverse healthcare settings and patient

populations is highly variable.²⁴⁻²⁷ Model deployment itself brings forth its own set of 116 challenges. From data curation to quality assurance and continuous monitoring, successful 117 integration requires a multifaceted and deliberate approach.^{28,29} In addition, designing and 118 119 implementing a workflow solution for clinicians to act on the outputs of an ML model requires additional training and personnel.³⁰ Clinical perceptions of ML interventions will also vary 120 121 depending on intuition and understanding, demonstrating that model accuracy does not necessarily equate to trust by providers and overall solution effectiveness.³¹ Taken together with 122 123 the privacy concerns related to use and sharing of protected healthcare data, external validations 124 of ML models are limited.

125 In this paper, we describe the external validation of the SepsisWatch model in Summa 126 Health, a hospital system in Ohio—a setting both geographically and temporally distinct from 127 the context of initial development at Duke University. SepsisWatch is the first deep learning 128 model implemented in routine clinical care in the United States and has been in continuous 129 operations at Duke University since November 2018. This study has two primary objectives. 130 First, we aim to assess the model's performance in this new environment. Second, we aim to 131 estimate the potential workload and benefit to patients associated with the prospective 132 implementation of SepsisWatch in this new environment. Through this study, we hope to 133 contribute meaningful insights into the broader applicability of ML models for sepsis detection, emphasizing the importance of context and adaptation. 134

135

136 Methods

137

139

138 Setting

140 Summa Health, a nonprofit integrated healthcare delivery system in Northeast Ohio,

141 encompasses two acute care hospitals: Summa Health Akron City Hospital (ACH) and Summa

142 Health Barberton (SHB), each equipped with their own emergency department (ED). The system 143 is further complemented by two standalone EDs—ACH Green ED and SHB Wadsworth ED. 144 These facilities form a 1,300-bed system that facilitates over one million patient encounters 145 annually. Summa Health primarily serves Summit, Wayne, Medina, Portage and Stark Counties 146 in Ohio. The service area encompasses urban, suburban, and rural areas. The payer mix of 147 Summa Health patients is 5% uninsured, 25% privately insured, 30% Medicaid, and 40% 148 Medicare.

149

150 Data

151 SepsisWatch was externally evaluated on encounters for adult patients (age ≥ 18) who 152 presented to one of Summa Health's four emergency departments (EDs) between 1/1/2020 and 12/31/2021. Encounters started at the time of presentation to the ED and ended at time of 153 154 discharge or death. Encounters were attributed to the site of origination, such that an encounter 155 that began at a free-standing ED and included a transfer to an acute hospital was assigned to the 156 free-standing ED. Each individual visit to the emergency department was considered as a 157 separate encounter, regardless of the number of visits made by the same patient. Encounters with 158 a length of stay less than 1-hour were excluded from the cohort and only the first 36 hours of 159 each encounter were used in the model evaluation.

160

161 The model combines static data that remains unchanged throughout an encounter and dynamic 162 data that is updated during an encounter. Static variables included patient demographics, 163

encounter details, and comorbidity data, which looked at ICD-10 codes documented at any

encounter in the 12 months prior to ED presentation. Dynamic data used by the model includes 164

analyte results, vital signs, and medication administrations. Dynamic variables were consideredbetween the encounter start time and end time.

167

168 *Outcome Definition*

169 We used a previously developed sepsis phenotype as our outcome label. Specifically, we defined 170 sepsis as the co-occurrence of all 3 following criteria: 1) At least two Systemic Inflammatory 171 Response Syndrome (SIRS) criteria, which is valid for 24 hours and includes temperature 172 anomalies (>100.4 F or <96.8 F), a heart rate above 90, a respiration rate exceeding 20, and an 173 abnormal white blood cell count (>12 or <4); (2) a blood culture order; (3) indication of any end-174 organ damage, characterized by elevated creatinine (>2.0), INR (>1.5), total bilirubin (>2.0), 175 decreased platelet count (<100), lactate levels of 2 or higher, or systolic blood pressure below 90 176 mmHg or a drop of 40 mmHg in systolic blood pressure within 6 hours. The varying sampling 177 rates for medical measurements were accounted for by adjusting the relevant time window for 178 each criterion. Vital sign documentation values (temperature, heart rate, respiration rate, blood 179 pressure) were valid for a six-hour time window, whereas analyte measurements (white blood 180 cell count, creatinine, bilirubin, platelet count, lactate) and orders (blood culture) were valid for a 24-hour time window. In addition, patients who met the criteria for sepsis within 1 hour of 181 182 presentation to the ED were excluded.

183 SepsisWatch was evaluated using a detection window of 12-hours, meaning once a 184 prediction breached the threshold, the prediction would only be classified as a true positive if the 185 patient met sepsis criteria within 12 hours. If the prediction breached the threshold more than 12 186 hours prior to sepsis, the prediction was classified as a false positive. SepsisWatch was ran 187 hourly on the hour, and produced predictions for all encounters between presenting to the ED

and the minimum of time of sepsis, time of death, time of discharge, and 36 hours after ED
presentation. Once a prediction breached the threshold, predictions over the next 8 hours were
suppressed or snoozed. This 8-hour snooze window was designed to reduce false positive alerts
and downstream potential alert fatigue. The snooze window also avoided inflating performance
metrics by repetitively counting true positives.

193

194 *Model*

195 The original model was designed at Duke University Hospital using EHR encounter data from October 1st 2014 – December 1st 2015. It is a recurrent neural network (RNN) model and is 196 197 hereby referred to as SepsisWatch. The data used to train the model was split 80:10:10 for 198 training, internal validation and testing, respectively. The original model performed well in 199 multiple settings. Specifically, on an internal validation cohort SepsisWatch achieved an area 200 under the receiver operator curve (AUROC) of 0.882 and on a temporal validation cohort the 201 model achieved an AUROC of 0.943. The full details of the model development and evaluation 202 can be accessed in the original development, internal validation manuscripts and implementation manuscripts.^{18,28,32} 203

204

205 *Evaluation*

206 To answer our first research objective, we evaluated the model performance in the new

207 healthcare setting using precision, recall, area under the precision-recall curve (AUPRC), and

area under the receiver operator curve (AUROC). To better understand the performance of

209 SepsisWatch across the different ED and hospital sites, we separately evaluated the model at

210 each location within Summa Health.

212	To answer our second research objective, we conduct several additional analyses. First, to									
213	estimate the potential effect of model integration on clinical care, we quantified the average 'lead									
214	time', defined as the amount of time between a 'high risk' model prediction and a patient									
215	meeting sepsis criterion. This measure helps quantify the potential opportunity for earlier									
216	intervention. Lead time is only measured for true positive cases identified early by SepsisWatch.									
217	Second, to assess the workflow burden placed on staff, we assessed the number of alerts that									
218	would be sent to either a charge nurse or rapid response team (RRT) at a given model threshold.									
219	The lead time and number of alerts are calculated separately for each Summa Health site.									
220										
221 222	Results									
223 224	Cohort Characteristics									
225	In total 205,005 encounters from 101,584 unique patients met inclusion criteria for the study.									
226	Most patients were female (54.7%, $n = 112,223$) and the mean age was 50 (IQR, [38,71]). The									
227	incidence of sepsis within the first 36 hours of encounters was 3.38% (n = 6,920). The majority									
228	of encounters were initiated at the two EDs co-located with acute care hospitals: ACH									
229	Emergency Department (ED) (59.08%, $n=121,131$) and SHB ED (23.53%, $n=48,244$). The									
230	remaining encounters were initiated at the two standalone EDs: ACH Green ED (11.11%, $n =$									
231	22,893) and SHB Wadsworth ED (6.21%, $n = 12,737$). Patient characteristics are broken down									
232	by site in Table 1 .									
233 234 235	Research Objective 1 - Model Performance									
236	Overall, the SepsisWatch model demonstrated robust performance on the geographically and									

237 temporally distinct Summa Health patient population. Moreover, there was little variation in

238	model performance across the different emergency departments. Area under the precision-recall
239	curve (AUPRC) for the four sites was 0.252 for ACH ED, 0.248 for SHB ED, 0.177 for ACH
240	Green ED and 0.216 for SHB Wadsworth ED. The area under the receiver operator curve
241	(AUROC) for the four sites was 0.919 for ACH ED, 0.906 for SHB ED, 0.960 for ACH Green
242	ED and 0.928 for SHB Wadsworth ED. The AUROC and AUPRC for the four sites are
243	visualized in Figure 1 and Figure 2. The model performed similarly at each distinct location
244	when stratifying patient population by White and Black races (Table 2).
245	
246	Research Objective 2 – Evaluating Potential Clinical Benefit and Alert Fatigue
247	Model performance measures, including precision, recall, average number of alerts per day, and
248	average lead time prior to meeting sepsis criteria vary based on model threshold. Performance
249	measures across thresholds are illustrated in Table 3. If a threshold is set at each site to fix
250	precision (positive predictive value) at 20%, the recall (sensitivity) is 76.2% at ACH ED, 70.9%
251	at SHB ED, 27.0% at ACH Green ED, and 61.2% at SHB Wadsworth ED. At this same
252	threshold, the average number of alerts per day is 7 at ACH ED, 3 at SHB ED, 2 at ACH Green
253	ED, and 1 at SHB Wadsworth ED. Lastly, the average lead time (hours) is 4.06 at ACH ED, 3.79
254	at SHB ED, 5.07 at ACH Green ED, and 3.58 at SHB Wadsworth ED (eTable 1 in the
255	Supplement).
256	
257	Alternatively, if a threshold is set at each site to fix recall (sensitivity) at 60%, the precision
258	(positive predictive value) is 23.9% at ACH ED, 23.1% at SHB ED, 16.3% at ACH Green ED,
259	and 20.1% at SHB Wadsworth ED. At this same threshold, the average number of alerts per day

260 is 7 at ACH ED, 3 at SHB ED, 1 at ACH Green ED, and 1 at SHB Wadsworth ED. Lastly, the

average lead time (hours) is 3.94 at ACH ED, 3.69 at SHB ED, 4.89 at ACH Green ED, and 3.42
at SHB Wadsworth ED (eTable 2 in the Supplement).

- 263
- 264 Discussion
- 265

266 In this study we present the first external validation of a sepsis ML model in a community 267 based health setting. The model was originally developed at a tertiary academic medical center in 268 North Carolina and maintained robust performance across four EDs at a community health system in Ohio. The original model achieved an AUROC of 0.83 and an AUPRC of 0.257.¹⁸ This 269 270 strong performance was maintained in the external validation presented in this study, in which 271 SepsisWatch achieved an AUROC of 0.92 and an AUPRC of 0.24. Moreover, SepsisWatch 272 performed strongly across two EDs that are co-located with acute care hospitals and two 273 standalone EDs, marking the first known validation of a sepsis machine learning algorithm in a 274 standalone ED. A 'Model Facts' sheet containing details of this external validation and the 275 original model development can be seen in eFigure 1 in the Supplement. 276 Most machine learning algorithms are not externally validated and those that are 277 demonstrate varied performance. Wong et al. demonstrated that the proprietary Epic Sepsis 278 Model (ESM) had substantially worse calibration and discrimination among adult patients within 279 one US academic health system. A later study by Lyons et al. also revealed and varied 280 performance of ESM across nine hospitals and found that hospitals with lower sepsis incidence had worse AUROC.²⁴ On the other hand, Brajer et al. demonstrated robust performance of an in-281

hospital mortality ML model across multiple hospitals within the same health system.²⁵ Moor *et*

- al. used a novel validation technique pooling predictions of models developed on different data,
- achieving an AUROC of 0.76 on external validation cohorts verse 0.84 on internal validation.³³
- 285 While Moor *et al.* were able improve external validation performance after fine tuning the

models using a small set of data from the target testing site, performance remained stronger in the internal validation cohort.³³ The new version of the ESM similarly includes fine tuning on local data to improve performance, but improved performance of that model has not yet been reported in the peer-reviewed literature. In addition, local fine tuning necessitates additional expertise, personnel, and compute infrastructure.

291 Beyond generalizing across time and geographic settings, SepsisWatch also exhibited 292 strong and robust performance across demographic subgroups. Unfortunately, examination of 293 ML model performance across racial subgroups has not been reported in many prior external validation studies in sepsis and other clinical domains.^{27,33} There are significant concerns when 294 295 models are trained on datasets with minimal diversity and tested on populations that include more representation of historically marginalized populations.³⁴ The current study builds on prior 296 work from dermatology that found that training on more diverse datasets led to improved 297 performance on diverse populations.³⁵ SepsisWatch was trained on a cohort of adults in North 298 299 Carolina that were 30% Black and performed well on cohorts of adults in Ohio that were 3% -300 30% Black. The robust performance of the SepsisWatch model presented in the current study 301 emphasizes the importance of training models on diverse datasets.

Balancing alert fatigue with clinically meaningful predictions is a well-established challenge in operationalizing sepsis prediction models.^{27,36,37} Moreover, given expected tradeoffs between model precision and recall, choosing a prediction threshold that balances both overall performance with clinical impact becomes exceedingly important. For example, at the ACH Emergency Department, when prediction threshold was set to 0.1, the model would send on average 147 alerts per day. At this threshold the model would identify almost every instance of sepsis and provide an average lead time of 7.1 hours. But the precision of the model at this

309 threshold is 2.1% and approximately 47 alerts need to be screened for every case that goes on to 310 develop sepsis. In contrast, a prediction threshold of 0.6 would afford a recall of 84%, precision 311 of 20% and average lead time of 4.23 hours. The number of alerts at this threshold is reduced 312 80% to an average of 29 alerts per day. Thus, operational leaders within each setting can titrate 313 the model threshold to align with the capacity of front-line clinicians to respond to alerts. 314 Ultimately, the threshold should be determined after a silent trial in which front-line clinicians 315 can help test SepsisWatch and ensure that patients flagged by the model are appropriate for 316 review.

317 Our study had several limitations. First, this was a retrospective study and while model 318 performance and potential opportunity to improve care could be assessed, SepsisWatch will need 319 to be prospectively tested to measure impact. Second, this study features a single health system 320 in a single geography. The generalizability of SepsisWatch beyond North Carolina and Ohio 321 remains unknown. Third, this study did not directly compare SepsisWatch to other available 322 sepsis models, such as the Epic Sepsis Model or TREWS. Those technologies were not available 323 to include in the analysis and additional contracting and potential costs would be required to 324 compare multiple algorithms. Future comparative effectiveness research will be required to 325 better understand the tradeoffs associated with use of each model. Fourth, this study evaluated 326 SepsisWatch during a time window that included the COVID-19 pandemic. The time window 327 was two years and covered multiple variant waves of the virus. Future research will be needed to 328 characterize variability of model performance during viral outbreaks. Finally, this study only 329 evaluated the performance of SepsisWatch with an 8-hour snooze window. Future studies are 330 necessary to optimize and tailor this time window for different implementation sites.

331

332 Conclusions

This study illustrates the first successful external validation of a sepsis deep learning model, SepsisWatch, within a community health system. SepsisWatch demonstrated remarkable consistency in performance despite variations in time, geography, and patient demographics. The strong performance of SepsisWatch highlights the possibility of effectively transporting advanced ML models from academic to community based hospital settings. Additionally, the study addresses the crucial balance between minimizing alert fatigue and maintaining clinical relevance, emphasizing the importance of carefully selecting prediction thresholds tailored to each deployment site and clinical context. The findings suggest that while there are challenges in creating more broadly applicable clinical prediction models, careful evaluation in different health contexts is feasible and can yield promising results. This study will pave the way for future prospective studies to measure the clinical and operational effect of SepsisWatch and other sepsis machine learning models integrated into clinical care.

363 References 364 365 1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International 366 Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-538. doi:10.1007/s00134-367 003-1662-x 368 2. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 369 independent cohorts. JAMA. 2014;312(1):90-92. doi:10.1001/jama.2014.5804 370 3. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and 371 mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet Lond Engl. 372 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7 373 4. Buchman TG, Simpson SQ, Sciarretta KL, et al. Sepsis Among Medicare Beneficiaries: 1. The 374 Burdens of Sepsis, 2012-2018. Crit Care Med. 2020;48(3):276-288. 375 doi:10.1097/CCM.00000000004224 376 5. Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and Costs of Sepsis in 377 the United States-An Analysis Based on Timing of Diagnosis and Severity Level. Crit Care 378 Med. 2018;46(12):1889-1897. doi:10.1097/CCM.00000000003342 379 6. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International 380 Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 381 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6 382 7. Cohen J, Vincent JL, Adhikari NKJ, et al. Sepsis: a roadmap for future research. Lancet Infect 383 Dis. 2015;15(5):581-614. doi:10.1016/S1473-3099(15)70112-X 384 8. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective 385 antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care 386 Med. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9 387 9. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in 388 severe sepsis and septic shock from the first hour: results from a guideline-based performance 389 improvement program. Crit Care Med. 2014;42(8):1749-1755. doi:10.1097/CCM.00000000000330 390 391 Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital 10. 392 Mortality in Sepsis. Am J Respir Crit Care Med. 2017;196(7):856-863. 393 doi:10.1164/rccm.201609-1848OC 394 11. Peltan ID, Brown SM, Bledsoe JR, et al. ED Door-to-Antibiotic Time and Long-term 395 Mortality in Sepsis. Chest. 2019;155(5):938-946. doi:10.1016/j.chest.2019.02.008 396 12. Rhee C, Yu T, Wang R, et al. Association Between Implementation of the Severe Sepsis 397 and Septic Shock Early Management Bundle Performance Measure and Outcomes in Patients 398 With Suspected Sepsis in US Hospitals. JAMA Netw Open. 2021;4(12):e2138596. 399 doi:10.1001/jamanetworkopen.2021.38596

- Townsend SR, Phillips GS, Duseja R, et al. Effects of Compliance With the Early
 Management Bundle (SEP-1) on Mortality Changes Among Medicare Beneficiaries With
 Sepsis: A Propensity Score Matched Cohort Study. *Chest.* 2022;161(2):392-406.
 doi:10.1016/j.chest.2021.07.2167
- 404 14. Barbash IJ, Davis BS, Yabes JG, Seymour CW, Angus DC, Kahn JM. Treatment Patterns
 405 and Clinical Outcomes After the Introduction of the Medicare Sepsis Performance Measure
 406 (SEP-1). Ann Intern Med. 2021;174(7):927-935. doi:10.7326/M20-5043
- 407 15. Henry KE, Hager DN, Pronovost PJ, Saria S. A targeted real-time early warning score
 408 (TREWScore) for septic shock. *Sci Transl Med.* 2015;7(299):299ra122.
 409 doi:10.1126/scitranslmed.aab3719
- 410 16. Desautels T, Calvert J, Hoffman J, et al. Prediction of Sepsis in the Intensive Care Unit
 411 With Minimal Electronic Health Record Data: A Machine Learning Approach. *JMIR Med*412 *Inform.* 2016;4(3):e28. doi:10.2196/medinform.5909
- Horng S, Sontag DA, Halpern Y, Jernite Y, Shapiro NI, Nathanson LA. Creating an
 automated trigger for sepsis clinical decision support at emergency department triage using
 machine learning. *PLOS ONE*. 2017;12(4):e0174708. doi:10.1371/journal.pone.0174708
- 416 18. Bedoya AD, Futoma J, Clement ME, et al. Machine learning for early detection of sepsis:
 417 an internal and temporal validation study. *JAMIA Open*. 2020;3(2):252-260.
 418 doi:10.1093/jamiaopen/ooaa006
- 419 19. Tarabichi Y, Cheng A, Bar-Shain D, et al. Improving Timeliness of Antibiotic
 420 Administration Using a Provider and Pharmacist Facing Sepsis Early Warning System in the
 421 Emergency Department Setting: A Randomized Controlled Quality Improvement Initiative.
 422 Controlled Quality Improvement Initiative.
- 422 *Crit Care Med.* 2022;50(3):418-427. doi:10.1097/CCM.00000000005267
- 423 20. Adams R, Henry KE, Sridharan A, et al. Prospective, multi-site study of patient outcomes
 424 after implementation of the TREWS machine learning-based early warning system for sepsis.
 425 *Nat Med.* 2022;28(7):1455-1460. doi:10.1038/s41591-022-01894-0
- 426 21. Shimabukuro DW, Barton CW, Feldman MD, Mataraso SJ, Das R. Effect of a machine
 427 learning-based severe sepsis prediction algorithm on patient survival and hospital length of
 428 stay: a randomised clinical trial. *BMJ Open Respir Res.* 2017;4(1):e000234.
- doi:10.1136/bmjresp-2017-000234
- 430 22. Nelson JL, Smith BL, Jared JD, Younger JG. Prospective trial of real-time electronic
 431 surveillance to expedite early care of severe sepsis. *Ann Emerg Med.* 2011;57(5):500-504.
 432 doi:10.1016/j.annemergmed.2010.12.008
- 433 23. Giannini HM, Ginestra JC, Chivers C, et al. A Machine Learning Algorithm to Predict
 434 Severe Sepsis and Septic Shock: Development, Implementation, and Impact on Clinical
 435 Practice. *Crit Care Med.* 2019;47(11):1485-1492. doi:10.1097/CCM.00000000003891

- 436 24. Lyons PG, Hofford MR, Yu SC, et al. Factors Associated With Variability in the
 437 Performance of a Proprietary Sepsis Prediction Model Across 9 Networked Hospitals in the
 438 US. *JAMA Intern Med.* 2023;183(6):611-612. doi:10.1001/jamainternmed.2022.7182
- 439 25. Brajer N, Cozzi B, Gao M, et al. Prospective and External Evaluation of a Machine
 440 Learning Model to Predict In-Hospital Mortality of Adults at Time of Admission. *JAMA Netw*441 *Open.* 2020;3(2):e1920733. doi:10.1001/jamanetworkopen.2019.20733
- 442 26. Bedoya AD, Clement ME, Phelan M, Steorts RC, O'Brien C, Goldstein BA. Minimal
 443 Impact of Implemented Early Warning Score and Best Practice Alert for Patient Deterioration.
 444 *Crit Care Med.* 2019;47(1):49-55. doi:10.1097/CCM.0000000003439
- Wong A, Otles E, Donnelly JP, et al. External Validation of a Widely Implemented
 Proprietary Sepsis Prediction Model in Hospitalized Patients. *JAMA Intern Med.*2021;181(8):1065-1070. doi:10.1001/jamainternmed.2021.2626
- Sendak MP, Ratliff W, Sarro D, et al. Real-World Integration of a Sepsis Deep Learning
 Technology Into Routine Clinical Care: Implementation Study. *JMIR Med Inform.*2020;8(7):e15182. doi:10.2196/15182
- 451 29. Sendak M, Sirdeshmukh G, Ochoa T, et al. Development and Validation of ML-DQA -- a
 452 Machine Learning Data Quality Assurance Framework for Healthcare. Published online
 453 August 4, 2022. doi:10.48550/arXiv.2208.02670
- 30. Topiwala R, Patel K, Twigg J, Rhule J, Meisenberg B. Retrospective Observational Study
 of the Clinical Performance Characteristics of a Machine Learning Approach to Early Sepsis
 Identification. *Crit Care Explor.* 2019;1(9):e0046. doi:10.1097/CCE.00000000000046
- 457 31. Ginestra JC, Giannini HM, Schweickert WD, et al. Clinician Perception of a Machine
 458 Learning-Based Early Warning System Designed to Predict Severe Sepsis and Septic Shock.
 459 *Crit Care Med.* 2019;47(11):1477-1484. doi:10.1097/CCM.00000000003803
- 460 32. Futoma J, Hariharan S, Heller K, et al. An Improved Multi-Output Gaussian Process
 461 RNN with Real-Time Validation for Early Sepsis Detection. In: *Proceedings of the 2nd*462 *Machine Learning for Healthcare Conference*. PMLR; 2017:243-254. Accessed September
 463 26, 2023. https://proceedings.mlr.press/v68/futoma17a.html
- 464 33. Moor M, Bennett N, Plečko D, et al. Predicting sepsis using deep learning across
 465 international sites: a retrospective development and validation study. *eClinicalMedicine*.
 466 2023;62:102124. doi:10.1016/j.eclinm.2023.102124
- 467 34. Chen IY, Pierson E, Rose S, Joshi S, Ferryman K, Ghassemi M. Ethical Machine
 468 Learning in Healthcare. *Annu Rev Biomed Data Sci.* 2021;4:123-144. doi:10.1146/annurev469 biodatasci-092820-114757
- 470 35. Daneshjou R, Vodrahalli K, Novoa RA, et al. Disparities in dermatology AI performance
 471 on a diverse, curated clinical image set. *Sci Adv.* 2022;8(32):eabq6147.
- doi:10.1126/sciadv.abq6147

- 473 36. Gregory ME, Russo E, Singh H. Electronic Health Record Alert-Related Workload as a
- 474 Predictor of Burnout in Primary Care Providers. *Appl Clin Inform.* 2017;08(3):686-697.
 475 doi:10.4338/ACI-2017-01-RA-0003
- 476 37. Borowski M, Görges M, Fried R, Such O, Wrede C, Imhoff M. Medical device alarms.
 477 2011;56(2):73-83. doi:10.1515/bmt.2011.005

79 Tables

Baseline Characteristics of Cohort	ACH EMERGENCY DEPT	SHB EMERGENCY DEPT	ACH GREEN ED	SHB WADSWORTH ED			
Total Encounters, N (%)	121131 (59.08%)	48244 (23.53%)	22893 (11.11%)	12737 (6.21%)			
Age (years), mean ±SD	50.92 ± 20.12	50.71 ± 20.18	47.36 ± 19.28	48 ± 20.05			
Sex Male, N (%)	56540 (46.67%)	21,284 (44.12%)	9,552 (41.72%)	5,551 (43.58%)			
Sex Female, N (%)	64470 (53.22%)	26,960 (55.88%)	13,341 (58.28%)	7,184 (56.40%)			
Sex (Others/Missing), N (%)	121 (0.10%)	0 (0%)	0 (0%)	2 (0.02%)			
Race, N (%)							
Black or African American	36431 (30.08%)	6,545 (13.57%)	2,436 (10.64%)	279 (2.19%)			
Caucasian/White	75833 (62.60%)	40,754 (84.47%)	20,086 (87.74%)	12,242 (96.11%)			
Missing/other	8867 (7.32%)	945 (1.96%)	371 (1.62%)	216 (1.70%)			
Comorbidities, N (%)							
Congestive heart failure	4515 (3.73%)	1,222 (2.53%)	257 (1.12%)	192 (1.51%)			
Hypertension	5805 (4.80%)	1,581 (3.28%)	534 (2.33)	479 (3.80%)			
Pulmonary circulation disorders	5441 (4.49%)	2,777 (5.76%)	633 (2.77%)	459 (3.60%)			
Diabetes mellitus	3702 (3.06%)	1,012 (2.10%)	283 (1.24%)	205 (1.61%)			
Fluid and electrolyte disorders	9324 (7.70%)	3,705 (7.68%)	995 (4.35%)	642 (5.04%)			
Depression	2521 (2.08%)	612 (1.27%)	141 (0.62%)	161 (1.26%)			
In-hospital mortality, N (%)	1139 (0.94%)	381 (0.79%)	0.16%	0.28%			
Median Length of Stay (25%–75%)	6.38 (3.5, 56.7)	4 (2.46, 28.8)	2.63 (1.71, 4.15)	2.43 (1.6, 4.31)			
Overall rate of ICU admission, N (%)	5487 (4.53%)	2644 (5.48%)	272 (1.19%)	320 (2.51%)			
Septic, N (%)	4639 (3.83%)	1785 (3.70%)	240 (1.05%)	245 (1.92%)			

Table 1: Description of cohort characteristics across all four emergency departments in the Summa Health system.

Table 2: Site-specific performance metrics stratified by race including area under the precision

recall curve (AU-PR) and area under the receiver operator curve (AUROC)

Cohort	AU-PR	AUROC	
ACH ED			
Entire Population	0.252	0.919	
White Adults	0.255	0.918	
Black Adults	0.238	0.911	
SHB ED			
Entire Population	0.248	0.906	
White Adults	0.246	0.901	
Black Adults	0.286	0.920	
ACH Green ED			
Entire Population	0.177	0.960	
White Adults	0.175	0.957	
Black Adults	0.18	0.983	
SHB- Wadsworth ED			
Entire Population	0.216	0.928	
White Adults	0.213	0.926	
Black Adults	0.325	0.974	

Threshold	d ACH Emergency Department			ment	SHB Emergency Department			ACH Green Emergency Department				SHB Wadsworth Emergency Department				
	Alerts/Day (95% CI)	Average lead time (95% CI)	Precision	Recall	Alerts per day (95% CI)	Lead time (hours) (95% CI)	Precision	Recall	Alerts/Day (95% CI)	Average lead time (95% CI)	Precision	Recall	Alerts/Day (95% CI)	Average lead time (95% CI)	Precision	Recall
0.1	147 (144, 148)	7.1 (6.9, 7.31)	0.021	0.986	60 (58, 61)	6.45 (6.16, 6.76)	0.024	0.975	28 (27, 28)	7.77 (6.82, 8.73)	0.009	0.988	15 (15,16)	6.05 (5.24, 6.87)	0.015	0.992
0.2	42 (41, 43)	4.97 (4.81, 5.15)	0.051	0.949	17 (17, 18)	4.69 (4.43, 4.95)	0.047	0.946	5 (4, 5)	6.11 (5.27, 6.97)	0.014	0.980	3 (3, 4)	4.79 (4.03, 5.56)	0.025	0.951
0.3	34 (32, 35)	4.60 (4.44, 4.78)	0.161	0.922	14 (13, 14)	4.31 (4.06, 4.57)	0.149	0.901	4 (3, 4)	5.59 (4.79, 6.41)	0.092	0.959	3 (3, 3)	4.27 (3.54, 5.01)	0.134	0.927
0.4	32 (30, 32)	4.43 (4.27, 4.6)	0.186	0.899	13 (12, 13)	4.13 (3.88, 4.39)	0.176	0.873	4 (3, 4)	5.47 (4.67, 6.29)	0.118	0.951	3 (3, 3)	4.01 (3.32, 4.72)	0.171	0.910
0.5	30 (29, 31)	4.31 (4.15, 4.48)	0.193	0.872	13 (12, 13)	4.04 (3.79, 4.3)	0.183	0.849	3 (3, 4)	5.37 (4.57, 6.18)	0.125	0.934	3 (3, 3)	3.84 (3.16, 4.52)	0.177	0.890
0.6	29 (28, 30)	4.23 (4.07, 4.4)	0.195	0.838	12 (11, 12)	3.94 (3.69, 4.2)	0.186	0.821	3 (3, 4)	5.25 (4.44, 6.07)	0.128	0.910	3 (3, 3)	3.72 (3.06, 4.4)	0.179	0.861
0.7	29 (28, 30)	4.12 (3.96, 4.29)	0.195	0.794	12 (11, 12)	3.85 (3.6, 4.11)	0.184	0.772	3 (3, 4)	5.13 (4.33, 5.94)	0.127	0.857	3 (3, 3)	3.65 (2.98, 4.32)	0.172	0.796
0.8	25 (24, 25)	4.02 (3.85, 4.19)	0.211	0.730	10 (9, 11)	3.73 (3.48, 3.99)	0.199	0.710	3 (2, 3)	4.96 (4.16, 5.76)	0.137	0.775	2 (2, 2)	3.51 (2.84, 4.19)	0.182	0.743
0.9	14 (14, 15)	3.86 (3.69, 4.04)	0.258	0.548	6 (5, 6)	3.62 (3.35, 3.89)	0.255	0.545	2 (2, 2)	4.74 (3.92, 5.57)	0.168	0.578	2 (2, 2)	3.15 (2.47, 3.84)	0.199	0.518
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

520 Table 3: Site specific model performance including precision, recall, average number of alerts per day and average lead time based on521 model threshold.



Figure 1: Area under the receiver operator curve at each of Summa Health's four emergency departments, A) ACH Emergency Department (ED), B) SHB ED, C) ACH Green ED, D) SHB Wadsworth ED



Figure 2: Area under precision-recall curve at each of Summa Health's four emergency departments A) ACH Emergency Department (ED) B) SHB ED C) ACH Green ED D) SHB Wadsworth ED